ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

ResMed (NYSE:RMD) intends to keep its CPAP masks that utilize magnets on the market despite a recall because it regards the action as a labeling correction rather than a product removal. According to ...

The last 12 months have been nothing short of a whirlwind for ResMed. After finding itself scrambling to pick up the slack left in the wake of Philips’ massive respiratory device recall last June, it ...

Dublin, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Care Devices Market by Product (PAP Devices, Ventilators, Humidifiers, Oxygen Concentrators, Spirometers, Peak Flow Meter, Masks), Disease ...

Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only. A replay of the earnings webcast will be accessible on ...

Medical device company ResMed (NYSE:RMD) in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit of $2.55 per share was 2.1% above analysts’ consensus estimates. Is now the ...

Medical device company ResMed (NYSE:RMD) will be reporting earnings this Thursday afternoon. Here’s what investors should know. ResMed met analysts’ revenue expectations last quarter, reporting ...

Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only. A replay of the earnings webcast will be accessible on ...